Australian
Prime Minister Scott Morrison,
media
release,
8 April 2021:
Earlier
this evening the Australian Government received advice from the
vaccine expert taskforce, the Australian Technical Advisory Group on
Immunisation (ATAGI).
The
detail of that advice is attached.
The
Government accepts the advice from Australia’s medical experts and
will move swiftly to ensure Australia’s vaccination program and
advice to patients is adjusted accordingly.
The
Australian Government places safety above all else, as it has done
throughout the pandemic, and will continue to follow the medical
advice in protecting Australians.
The
ATAGI advice is clear that the AstraZeneca COVID-19 vaccine is highly
effective in preventing severe disease caused by COVID-19.
The
medical advice to the Government is that the risk of blood clotting
side effects from the Astra Zeneca vaccine is four to six in one
million people, in the first four to 20 days post the vaccine. This
is a rare but serious side effect.
On
that basis, the recommendation is that it is preferred that the
Pfizer vaccine be provided to adults under the age of 50. The
AstraZeneca vaccine should only be given as a first dose to adults
under the age of 50 where the benefit clearly outweighs the risk for
that individual.
AstraZeneca
is recommended for those over the age of 50.
The
vaccination program will continue, particularly for the most
vulnerable Australians in Phase 1B including those over the age of 70
who are not impacted by this revised advice.
The
longer term timeframe for the program is being reviewed following
this medical advice.
The
Department of Health will provide preliminary, updated advice to
general practitioners and health professionals.
The
ATAGI advice follows further international evidence including from
the vaccinations in Europe and the United Kingdom. ATAGI had already
provided updated guidance on 2 April.
The
ATAGI advice has today been considered by the Australian Health
Protection Principal Committee (AHPPC), which is the Medical Expert
Panel led by the Chief Medical Officer, and also comprising all State
and Territory Chief Health Officers.
The
advice will be provided to National Cabinet tomorrow.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The
Australian Technical Advisory Group on Immunisation (ATAGI) advice on
the AstraZeneca COVID-19 vaccine in response to new vaccine safety
concerns,
excerpts;
“Definitions
Thrombosis
with thrombocytopenia syndrome (TTS) is a rare and new syndrome which
hasbeen reported after being given the AstraZeneca COVID-19 vaccine.
It may be caused by this vaccine. The condition involves blood clots
(occurring in body sites like the brain or abdomen) together with low
platelet levels.
Thrombosis
is the formation of a blood clot, which prevents blood flowing
normally through the
body.
Thrombocytopenia
is a condition in which you have a low blood platelet count.
Platelets (thrombocytes) are blood cells that help blood clot.
Platelets stop bleeding by clumping and forming
plugs in blood vessel injuries.”
“ The
AstraZeneca vaccine appears likely to be causally-linked with a risk
of this newly recognised thrombosis with thrombocytopenia syndrome.
There
is currently uncertainty in, and different reported rates of risk,
for this adverse event.
Studies
have suggested it may occur in approximately 4 – 6 people in every
one million people in the 4-20 days after the first dose of vaccine.
However, higher rates have been reported in Germany and some
Scandinavian countries.
Some
evidence suggests the risk of this condition occurring may be
somewhat higher in people of a younger age, however a small number of
cases have been reported in people of different ages (including older
adults).
While
there have been more reports of TTS in women in some settings, this
may be because more vaccine doses have been given to women. In one
country the reported rate of TTS (number of cases adjusted for the
number of men and women vaccinated) was similar in men and women.
TTS
can cause serious long term disability or death (with death occurring
in approximately 25% of reported cases).
So
far no specific biological risk factors or pre-existing medical
conditions have been found to modify (i.e. increase or decrease) the
risk of TTS occurring after AstraZeneca vaccine.
We
do not yet know to what extent earlier recognition of this syndrome
and improved treatments will improve patient outcomes. More cases can
be expected to occur, albeit rarely.
Comirnaty
(the Pfizer COVID-19 vaccine) does not appear to carry a risk of TTS.
[my
yellow highlighting]
NOTE: On 13 July 2020 AstraZeneca shares were worth US$61.10. By 8 April 2021 share price has fallen to US$49.78.